Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What CAGR Is Anticipated for the Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Through 2029?#_x000D_
In the past few years, the market size for chimeric antigen receptor-natural killer (CAR-NK) cell therapy has seen robust growth. The market value, which stands at $2.27 billion in 2024, is projected to increase to $2.42 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%. The substantial growth experienced during the historic period is due to factors such as the global rise in cancer cases, heightened emphasis on immunotherapy, the early clinical victories achieved with natural killer (NK) cell therapies, government support for cancer research, and the growth of cell therapy production facilities._x000D_
_x000D_
The market for chimeric antigen receptor-natural killer (CAR-NK) cell therapy is set to experience substantial growth in the coming years, with a projection to reach $3.09 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.3%. Factors contributing to such notable growth within the forecast period include increased investment in cellular immunotherapy, growth in partnerships between biotech and pharmaceutical companies, increased demand for ready-to-use cancer treatments, growth in clinical trials for CAR-NK therapies, and the rise in precision oncology adoption. The period under forecast also sees major trends, such as advancements in genetic engineering, innovations in CAR construct design, the rise of allogeneic natural killer (NK) cell platforms, progress in tumor microenvironment modulation research, and the application of artificial intelligence (AI) in cell therapy development._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27254&type=smp_x000D_
_x000D_
#What Market Forces Are Driving The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Sector In 2025 And Beyond?#_x000D_
The global surge in cancer cases is likely to fuel the expansion of the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market. Such a disease, cancer, is constituted of several ailments typified by unchecked proliferation and dispersion of abnormal cells, potentially harming bodily organs. Ageing populace and unhealthy living contribute majorly to the uptick in cancer prevalence, as ageing leads to a rise in mutation accumulation and unhealthy practices like smoking, poor nutrition, and lack of physical activity heighten the risk of cancer. CAR-NK cell therapy facilitates cancer treatment by genetically modifying natural killer cells to accurately detect and eradicate cancerous cells, thereby bolstering the immune system’s focused onslaught on tumours. For example, the Switzerland-based intergovernmental institution, World Health Organization (WHO), estimated in February 2024 that the 20 million fresh cancer cases in 2022 might surge by 77%, resulting in over 35 million cases by 2050. Hence, the global surge in cancer cases propels the expansion of the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market._x000D_
_x000D_
#How Is The Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Categorized By Segments?#_x000D_
The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market covered in this report is segmented_x000D_
_x000D_
1) By Type: Cytokine Therapy, Adoptive Natural Killer (NK) Cell Therapy, Genetically Engineered Natural Killer Cell Therapy, Other Types_x000D_
2) By Cell Source: Peripheral Blood-Derived Natural Killer Cells, Cord Blood-Derived Natural Killer Cells, Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells, Natural Killer Cell Lines_x000D_
3) By Application: Solid Tumors, Hematological Malignancies, Other Applications_x000D_
4) By End User: Hospitals, Cancer Research Institutes, Biotechnology And Pharmaceutical Companies_x000D_
_x000D_
Subsegments:_x000D_
1) By Cytokine Therapy: Interleukin Therapy, Interferon Therapy, Colony Stimulating Factor Therapy, Tumor Necrosis Factor Therapy_x000D_
2) By Adoptive Natural Killer Cell Therapy: Autologous Natural Killer Cell Therapy, Allogeneic Natural Killer Cell Therapy, Expanded Natural Killer Cell Therapy, Activated Natural Killer Cell Therapy_x000D_
3) By Genetically Engineered Natural Killer Cell Therapy: Chimeric Antigen Receptor Natural Killer Cell Therapy, T Cell Receptor Engineered Natural Killer Cell Therapy, Gene Edited Natural Killer Cell Therapy, Cytokine Gene Modified Natural Killer Cell Therapy_x000D_
4) By Other Types: Combination Therapy, Immune Checkpoint Inhibitor Therapy, Antibody Dependent Cellular Cytotoxicity Therapy, Oncolytic Virus Therapy_x000D_
_x000D_
#What Long-Term Trends Are Likely To Affect The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market?#_x000D_
Prominent businesses within the chimeric antigen receptor-natural killer (CAR-NK) cell therapy realm are putting emphasis on the advancement of high-tech solutions like chemotherapy-free conditioning treatments. These treatments are geared towards developing cellular therapies that are less hazardous and more effective. Conditioning chemotherapy-free treatment is a therapeutic method that eradicates the prerequisite for intense chemotherapy procedures prior to the administration of cellular treatments. This reduces toxicity and mitigates side effects in patients. To illustrate, Fate Therapeutics Inc., a clinical-stage biopharmaceutical organization based in the US, in November 2024, launched FT522, a CD19-targeted CAR NK cell therapy taken straight off-the-shelf. This ground-breaking therapy integrates alloimmune defense receptor technology enabling the CAR NK cells to survive and selectively eliminate harmful B cells in patients suffering from recurring or refractory B-cell lymphoma and autoimmune diseases. This was shown to be successful in preliminary clinical trials without requiring intense immune system suppression._x000D_
_x000D_
#Which Firms Are Considered Leaders In The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Space?#_x000D_
Major companies operating in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market are Takeda Pharmaceutical Company Limited, Artiva Biotherapeutics Inc., Nkarta Inc., ImmunityBio Inc., Fate Therapeutics Inc., Acepodia Inc., PersonGen BioTherapeutics Inc., Cartherics Inc., Century Therapeutics Inc., Catamaran Bio Inc., Glycostem Therapeutics Ltd., ImmuneBridge Co. Ltd., ONK Therapeutics Inc., Senti Biosciences Inc., Wugen Therapeutics Inc., Chimeric Therapeutics Limited, East Ocyon Bio, Nuwacell Biotechnologies Co. Ltd., Nkarta Therapeutics Inc., and GICELL Co. Ltd. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
_x000D_
#What Role Do Regional Policies And Investments Play In Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Expansion?#_x000D_
North America was the largest region in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27254&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model